Pharmaceutics, Volume 13, Issue 3 (March 2021) – 139 articles
Cover Story (view full-size image): Methotrexate (MTX) application in the treatment of several diseases is limited by its poor solubility in biological fluids, its poor bioavailability, and its toxicity. Encapsulating its original form in nano-formulation is very arduous due to its solubility features. Two strategies to efficiently encapsulate MTX into liposomal particles are proposed in this study. MTX was conjugated to two different compounds, commonly enriching liposome formulations (DSPE and PEG). The two prodrugs (DSPE–MTX and PEG–MTX) were used to generate high drug content liposomes, which comprised one or both the molecules. These formulations represent an initial step in developing targeted liposomes or particles, which can be tailored for the specific applications that MTX is used for (cancer, autoimmune disease, etc.). View this paper.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.